Funding Received
$32.5 Million in 2 Rounds from 5 Investors
Most Recent Funding
$12.5 Million Series A on February 9, 2012
Headquarters:
South San Francisco, CA
Description:
Altheos was a biopharmaceutical company focused on the development of small molecule drugs.
Categories:
Biotechnology
Website:
http://altheos.net

Company Details

Update

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Past Team (4)

Update

Board Members and Advisors (2)

Update

Investors (5)

Update

Offices/Locations (1)

Update
  • Office

    400 Oyster Point Boulevard

    Suite 108

    South San Francisco, CA 94080

    USA